PHMMF (Pharma Mar) Other Current Liabilities: $37.4 Mil (As of Mar. 2026)


PHMMF Pharma Mar SA PHMMF
82 GF Score
Price $79.49
GF Value $90.28
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Other Current Liabilities?

Pharma Mar PHMMF -25.35% 82 Other Current Liabilities is $37.4 Mil as of Mar. 2026. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $90.28 (Fairly Valued). The stock has 3 warning signs investors should review.

Pharma Mar's other current liabilities for the quarter that ended in Mar. 2026 was $37.4 Mil.

Pharma Mar's quarterly other current liabilities increased from Sep. 2025 ($38.2 Mil) to Dec. 2025 ($43.5 Mil) but then declined from Dec. 2025 ($43.5 Mil) to Mar. 2026 ($37.4 Mil).

Pharma Mar's annual other current liabilities declined from Dec. 2023 ($52.8 Mil) to Dec. 2024 ($32.0 Mil) but then increased from Dec. 2024 ($32.0 Mil) to Dec. 2025 ($43.5 Mil).

Pharma Mar Other Current Liabilities Related Terms

Pharma Mar Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Other Current Liabilities Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.02 57.28 52.81 32.00 43.48

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.88 33.67 38.22 43.48 37.39
PHMMF
82GF Score
Pharma Mar SA PHMMF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $37.4 Mil mean?
Pharma Mar (PHMMF) has a Other Current Liabilities of $37.4 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharma Mar.
Is Pharma Mar's Other Current Liabilities too high?
Pharma Mar's current Other Current Liabilities is $37.4 Mil. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Other Current Liabilities compare to VRTX and REGN?
Pharma Mar's Other Current Liabilities of $37.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharma Mar. Pharma Mar's current Other Current Liabilities is $37.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $90.28, compared to a current price of $79.49 — trading 12% below its estimated fair value. The current Other Current Liabilities is $37.4 Mil. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Other Current Liabilities is $37.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (PHMMF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of $79.49 is trading 12% below its estimated GF Value™ of $90.28. GuruFocus considers Pharma Mar to be Fairly Valued.

Key valuation signals for PHMMF:

  • Other Current Liabilities: $37.4 Mil
  • GF Value™: $90.28 vs. price of $79.49 (12% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score

Get the complete analysis for PHMMF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.49
Price
$90.28
GF Value